These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 32250342)
1. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Alajati A; D'Ambrosio M; Troiani M; Mosole S; Pellegrini L; Chen J; Revandkar A; Bolis M; Theurillat JP; Guccini I; Losa M; Calcinotto A; De Bernardis G; Pasquini E; D'Antuono R; Sharp A; Figueiredo I; Nava Rodrigues D; Welti J; Gil V; Yuan W; Vlajnic T; Bubendorf L; Chiorino G; Gnetti L; Torrano V; Carracedo A; Camplese L; Hirabayashi S; Canato E; Pasut G; Montopoli M; Rüschoff JH; Wild P; Moch H; De Bono J; Alimonti A J Clin Invest; 2020 May; 130(5):2435-2450. PubMed ID: 32250342 [TBL] [Abstract][Full Text] [Related]
2. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer. Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563 [TBL] [Abstract][Full Text] [Related]
3. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226 [TBL] [Abstract][Full Text] [Related]
4. Regulation of inside-out β1-integrin activation by CDCP1. Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352 [TBL] [Abstract][Full Text] [Related]
5. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases. Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678 [TBL] [Abstract][Full Text] [Related]
6. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Casar B; He Y; Iconomou M; Hooper JD; Quigley JP; Deryugina EI Oncogene; 2012 Aug; 31(35):3924-38. PubMed ID: 22179830 [TBL] [Abstract][Full Text] [Related]
7. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells. Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839 [TBL] [Abstract][Full Text] [Related]
8. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929 [TBL] [Abstract][Full Text] [Related]
9. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491 [TBL] [Abstract][Full Text] [Related]
10. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
11. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330 [TBL] [Abstract][Full Text] [Related]
12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736 [TBL] [Abstract][Full Text] [Related]
13. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM Cancer Discov; 2013 Jan; 3(1):44-51. PubMed ID: 23258246 [TBL] [Abstract][Full Text] [Related]
14. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300 [TBL] [Abstract][Full Text] [Related]
15. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970 [No Abstract] [Full Text] [Related]
16. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
17. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer. Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208 [TBL] [Abstract][Full Text] [Related]
18. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer. Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544 [TBL] [Abstract][Full Text] [Related]
19. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076 [TBL] [Abstract][Full Text] [Related]
20. CUB domain-containing protein 1 (CDCP1) binds transforming growth factor beta family members and increase TGF-β1 signaling pathway. Predes D; Cruz JVR; Abreu JG; Mendes FA Exp Cell Res; 2019 Oct; 383(1):111499. PubMed ID: 31302030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]